Cilengitide

Generic Name: Cilengitide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀N_₈O_₇

CAS Number: 188968-51-6

Unique Ingredient Identifier: 4EDF46E4GI

Background: Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Phase 2

Completed

Conditions: Recurrent Childhood Anaplastic Astrocytoma
Recurrent Childhood Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Recurrent Childhood Anaplastic Oligoastrocytoma
Childhood High-grade Cerebellar Astrocytoma
Recurrent Childhood Anaplastic Oligodendroglioma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Brain Tumor
Recurrent Childhood Glioblastoma
Recurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2008-05-16

Last Posted Date: 2018-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00679354

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸
T C Thompson Children's Hospital, Chattanooga, Tennessee, United States

and more 17 locations

Cilengitide in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IIA Prostate Cancer
Stage III Prostate Cancer
Stage IIB Prostate Cancer
Stage I Prostate Cancer

Interventions: Drug: cilengitide

First Posted Date: 2005-07-21

Last Posted Date: 2016-04-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT00121238

Locations: 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Phase 2

Terminated

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: cilengitide
Procedure: therapeutic conventional surgery
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2005-06-03

Last Posted Date: 2017-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00112866

Locations: 🇺🇸
North American Brain Tumor Consortium, Watertown, Massachusetts, United States

Cilengitide in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis

First Posted Date: 2005-02-08

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT00103337

Locations: 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States

Cilengitide in Treating Patients With Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: cilengitide

First Posted Date: 2004-08-05

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00089388

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Leukemia
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Unspecified Adult Solid Tumor, Protocol Specific
Chronic Myeloproliferative Disorders

First Posted Date: 2004-07-26

Last Posted Date: 2014-09-17

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 40

Registration Number: NCT00004258

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: cilengitide
Drug: temozolomide
Radiation: radiation therapy
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2004-06-11

Last Posted Date: 2016-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 112

Registration Number: NCT00085254

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 5 locations

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Phase 1

Terminated

Conditions: Sarcoma

Interventions: Drug: cilengitide

First Posted Date: 2004-05-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00006222

Locations: 🇺🇸
Vanderbilt Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Phase 2

Terminated

Conditions: Stage III Melanoma
Stage IV Melanoma

Interventions: Drug: cilengitide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2004-05-19

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00082875

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: cilengitide

First Posted Date: 2004-02-11

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00077155

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy